Pestalozzi advises Roth Capital Partners in connection with underwriting of USD 10 million public offering of Auris Medical

Pestalozzi advises Roth Capital Partners in connection with underwriting of USD 10 million public offering of Auris Medical

21.02.2017

Auris Medical Holding AG, a Swiss clinical-stage company listed at NASDAQ (EARS) and dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, closed a public offering of 10,000,000 common shares and 10,000,000 warrants, each warrant entitling its holder to purchase 0.70 of a common share. The common shares and warrants were sold in units comprised of one common share and one warrant at a public offering price of USD 1.00 per unit. Auris Medical Holding AG also closed the sale of an additional 1,350,000 warrants pursuant to the underwriter's partial exercise of its 30-day option to purchase up to 1,500,000 additional common shares and/or 1,500,000 additional warrants at the public offering price less underwriting discounts. Roth Capital Partners acted as sole book-running manager in the offering. Pestalozzi advised Roth Capital Partners as to Swiss law.

Contact